habener glp-1 Professor Joel Francis Reflections on the discovery GLP-1
Description
J Clin Invest 2014;124:447388.PubMedPMC 40
Joint ADS/ANZSNM guideline for FDG PET/CT imaging in patients with type 1 and type 2 diabetes
Some secondary analyses had nominal significance in favor of tirzepatide, with a 16% reduction in all-cause mortality versus dulaglutide (HR 0.84
Additionally, both medications require specific administration instructions that must be followed to ensure optimal absorption and efficacy
I understand tirzepatide is a dual-action GIP/GLP-1 agonist and may produce stronger weight loss results, while semaglutide has a longer track record
